neurodegenerative disease studies – The Milli Chronicle

Monday, November 24, 2025

Latest:

Italian Authorities Expand Probe Into Alleged Customs and Tax Irregularities Involving Amazon and Chinese Imports
Novo Nordisk’s Alzheimer’s Trials Show No Benefit, Prompting Reassessment of GLP-1 Potential in Brain Health
Barrick and Mali Reach Comprehensive Agreement to Settle Gold Mine Dispute and Restore Operations
Telefonica’s Workforce Restructuring Plan Draws Union Attention
FTSE 100 Slips as Consumer Staples and Industrials Weigh on Index

Factual Version of a Story

Featured News World

NewsDesk Milli Chronicle November 24, 2025 Alzheimer’s biomarkers research, Alzheimer’s conference updates, biotech industry analysis, brain health clinical studies, cognitive decline trials, early Alzheimer’s treatment news, EVOKE study update, global dementia statistics, GLP-1 drug research, latest medical research news, neurodegenerative disease studies, Novo Nordisk Alzheimer’s trials, obesity drugmaker research expansion, pharmaceutical trial outcomes, semaglutide study results

Novo Nordisk’s Alzheimer’s Trials Show No Benefit, Prompting Reassessment of GLP-1 Potential in Brain Health

Novo Nordisk’s early-stage Alzheimer’s studies using an oral form of semaglutide did not slow cognitive decline, renewing questions about whether